Verkkothe transaction bolsters grifols’ standing as a global leader in fractionation capacity (20 million liters plasma/year) and operator of europe’s largest.

Verkkothe new plant further reflects grifols investment in europe and expands its current global capacity to meet rising demand for plasma medicines.

Verkkothe flagship grifols campus is a touchstone of grifols’ leadership in plasma therapeutics, producing about 40% of the company’s total medicinal output.

Recommended for you
You may also like

📖 Continue Reading:

Southland Car & Jeep Rentals